SELLAS Life Sciences Group, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
SELLAS Life Sciences Group, Inc. (SLS) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $7.95 million as of 2020-09-30, per its 10-Q filed 2020-11-13.
Discontinued › Balance Sheet › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2020-11-13
- 2020-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $7.95M.
- 2020-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $3.78M.
- 2020-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $8.06M.
- 2019-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $6.09M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2020-09-30 | $7.95M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $3.78M 10-Q · filed 2020-11-13 | |
| 2020-03-31 | $8.06M 10-Q · filed 2020-08-13 | |
| 2019-12-31 | $6.09M 10-Q · filed 2020-11-13 | |
| 2019-09-30 | $10.64M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $14.34M 10-Q · filed 2020-11-13 | |
| 2019-03-31 | $2.95M 10-Q · filed 2020-08-13 | |
| 2018-12-31 | $5.25M 10-Q · filed 2020-11-13 | |
| 2018-09-30 | $18.46M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$2.48M 10-Q · filed 2019-11-14 | |
| 2018-03-31 | -$1.32M 10-Q · filed 2019-08-14 | |
| 2017-12-31 | $2.07M 10-K · filed 2020-03-13 | |
| 2017-09-30 | $14.64M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $19.13M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $27.19M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | -$5.00M 10-K · filed 2019-03-22 | $28.66M 10-K · filed 2017-03-15 |
| 2016-09-30 | $23.93M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $20.32M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $12.41M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $13.51M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $32.42M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $49.37M 10-Q · filed 2015-08-06 | |
| 2014-12-31 | $37.06M 10-K · filed 2017-03-15 | |
| 2014-09-30 | $59.08M 10-Q · filed 2015-05-07 | $30.86M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $28.31M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $46.50M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $5.89M 10-K · filed 2017-03-15 | |
| 2013-09-30 | $34.62M 10-Q/A · filed 2013-11-07 | |
| 2012-12-31 | $27.76M 10-K/A · filed 2016-04-15 | |
| 2011-12-31 | $10.11M 8-K · filed 2015-12-04 | |
| 2010-12-31 | $2.43M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |